Skip to content

Reporting Hub

Three colleagues wearing masks and standing in front of a wall full of sticky notes look at a tablet device
Home
Reporting Hub
References

References

1 The tax information contained in this section is intended to provide the reader with an overview of all taxes contributed by Johnson & Johnson, and not just income taxes. It should be read in conjunction with the Company’s tax information filed with the U.S. Securities and Exchange Commission (SEC), including in the most recently filed Quarterly Reports on Form 10-Q and Annual Report on Form 10-K. This tax information is supplemental to, and not a substitute for, the information reported in the Company’s SEC filings.

2 WHO, "World Health Day 2021: health equity and its determinants," https://cdn.who.int/media/docs/default-source/world-health-day-2021/health-equity-and-its-determinants.pdf. Accessed February 2022.

3 HIMSS, "Global Health Disparities Infographic," https://www.himss.org/resources/global-health-disparities-infographic. Accessed February 2022.

4 CDC, https://www.cdc.gov/healthequity/features/maternal-mortality/. Accessed February 2022.

5 The Lancet, "The Lancet Global Health Commission on Global Eye Health: vision beyond 2020, Executive Summary," https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(20)30488-5/fulltext. Accessed February 2022.

6 The Johnson Medal for Research and Development is named in honor of General Robert Wood Johnson, Johnson & Johnson Chairman from 1932 to 1963 and author of Our Credo.

7 CARVYKTI is targeted for patients who previously received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody.

8 Known as DARZALEX SC or DARZQURO in other markets, this innovative regimen was also the first treatment approved for this indication by Health Canada and by the EMA and in other countries.

9 Johnson & Johnson, "RYBREVANT (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations," https://www.jnj.com/rybrevanttm-amivantamab-vmjw-receives-fda-approval-as-the-first-targeted-treatment-for-patients-with-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.

10 Benza R., et al, Chest, 2012, 142:448–56; Hoeper M.M., et al, European Respiratory Journal, 2021; in press.

11 Johnson & Johnson, "OPSYNVI (macitentan and tadalafil) Becomes the First and Only Health Canada-Approved Once Daily Fixed Dose Combination Treatment for Patients with Pulmonary Arterial Hypertension (PAH)," https://www.jnj.com/opsynvi-macitentan-and-tadalafil-becomes-the-first-and-only-health-canada-approved-once-daily-fixed-dose-combination-treatment-for-patients-with-pulmonary-arterial-hypertension-pah.

12 Johnson & Johnson, "FDA Approves Two New Indications for XARELTO (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients," https://www.jnj.com/fda-approves-two-new-indications-for-xarelto-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients. XARELTO (rivaroxaban) is targeted for (1) the treatment of blood clots and reduction in the risk of recurrent blood clots in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment, and (2) thromboprophylaxis (prevention of blood clots and blood clot-related events) in children aged 2 years and older with congenital heart disease who have undergone the Fontan procedure. XARELTO is the only direct oral anticoagulant (DOAC) FDA approved for primary prevention of clots in pediatric patients following the Fontan procedure and the only DOAC in the United States to offer an oral suspension formulation for flexible, body weight-adjusted dosing options for pediatric patients.

13 Includes atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, lupus nephritis, Sjögren’s syndrome, myositis, amyloidosis, hidradenitis suppurativa, graft vs. host disease, scleroderma, myasthenia gravis and celiac disease.

14 Janssen, "Janssen Showcases Phase 2 Nipocalimab (M281) Data in Adults with Generalized Myasthenia Gravis (gMG) at the 2021 American Academy of Neurology Virtual Meeting," https://www.janssen.com/janssen-showcases-phase-2-nipocalimab-m281-data-adults-generalized-myasthenia-gravis-gmg-2021.

15 The program consists of two Phase 2 studies: AXIOMATIC-TKR (NCT03891524,) evaluating milvexian to prevent blood clots after total knee replacement (TKR) surgery, and AXIOMATIC-SSP (NCT03766581), evaluating milvexian to prevent the recurrence of stroke.

16 Total number of procedures performed is determined by estimating total scope utilization. Total scope utilization is defined as: total number of scopes returned less the number of stock returns and scopes that are returned due to a customer complaint.

17 Female-led is defined as any company with a woman at the C-Level, including Co-Founder and minority are individuals that self-identify as racially or ethnically diverse in the United States.

18 The Lancet, "Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development," https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)60160-X/fulltext. Accessed February 2022.

19 Funded in part by the Johnson & Johnson Foundation, a registered charity and a company limited by guarantee, and by the Corporation and operating companies across the Johnson & Johnson Family of Companies. The Foundation operates worldwide as Johnson & Johnson Foundation (founded 1953) and Johnson & Johnson Foundation Scotland (founded 2007).

20 WHO, "Obstetric fistula," https://www.who.int/news-room/facts-in-pictures/detail/10-facts-on-obstetric-fistula. Accessed February 2022.

21 WHO, "WHO Special Initiative for Mental Health," https://www.who.int/initiatives/who-special-initiative-for-mental-health. Accessed February 2022.

22 Ibid.

23 WHO, "Schizophrenia," https://www.who.int/news-room/fact-sheets/detail/schizophrenia. Accessed February 2022.

24 WHO, World report on vision, https://www.who.int/publications/i/item/9789241516570.

25 Davis G., "The Evolution of Cataract Surgery," The Journal of the Missouri State Medical Association, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139750/.

26 Johnson & Johnson, "Johnson & Johnson Vision Expands 'Sight For Kids' Program to Bring Eye Care to More Children and Unveils New 'Vision for Good' Community Impact Report," https://www.jjvision.com/press-release/johnson-johnson-vision-expands-sight-kids-program-bring-eye-care-more-children-and.

27 CDC, "Skin Cancer," https://www.cdc.gov/cancer/skin/what_cdc_is_doing/index.htm. Accessed February 2022.

28 Funded in part by the Johnson & Johnson Foundation, a registered charity and a company limited by guarantee, and by the Corporation and operating companies across the Johnson & Johnson Family of Companies. The Foundation operates worldwide as Johnson & Johnson Foundation (founded 1953) and Johnson & Johnson Foundation Scotland (founded 2007).

29 Hu L., et al, "Integrating Health and Care in China: Lessons Learned and Future Outlook," https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8588902/. Accessed February 2022.

30 ANA Enterprise, "Year One COVID-19 Impact Assessment Survey," https://epicmsdev.nursingworld.org/practice-policy/work-environment/health-safety/disaster-preparedness/coronavirus/what-you-need-to-know/year-one-covid-19-impact-assessment- survey/. Accessed February 2022.

31 Figure as of November 2021.

32 Funded primarily by the Johnson & Johnson Foundation, a registered charity and a company limited by guarantee. The Foundation is a separate legal entity from the Johnson & Johnson Family of Companies. The Foundation operates worldwide as Johnson & Johnson Foundation (founded 1953) and Johnson & Johnson Foundation Scotland (founded 2007).

33 Updated on May 5th, 2022, see https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals.

34 HIV.gov, "The Global HIV/AIDS Epidemic," https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics. Accessed, February 2022.

35 In December 2020, the European Commission authorized the first complete, LAI treatment for HIV, which combines Janssen’s rilpivirine with ViiV Healthcare’s cabotegravir, offering people with HIV living in Europe the potential of replacing daily oral treatments with six injections per year (every other month) or twelve injections per year (every month), https://www.janssen.com/emea/sites/www_janssen_com_emea/files/ janssen_announces_european_commission_authorisation_of_the_first_complete_long- acting_injectable_hiv_treatment_in_europe.pdf.

36 Imbokodo was supported by a public–private partnership led by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson; the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health; the Bill & Melinda Gates Foundation; and the HIV Vaccine Trials Network (HVTN). Additional partners providing support included the U.S. Army Medical Research and Development Command and the Ragon Institute of MGH, MIT and Harvard. The study was conducted at clinical sites coordinated by HVTN, and the South African Medical Resource Council (SAMRC) helped to implement Imbokodo in South Africa.

37 Thomson KA, Hughes J, Baeten JM, et al., "Increased Risk of Female HIV-1 Acquisition Throughout Pregnancy and Postpartum: A Prospective Per-coital Act Analysis Among Women with HIV-1 Infected Partners," The Journal of Infectious Diseases, 2018 June 5.

38 Paton N.I., et al, "Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV," https://www.nejm.org/doi/pdf/10.1056/NEJMoa2101609.

39 WHO, "Global tuberculosis report 2021," https://www.who.int/publications/i/item/9789240037021. Accessed February 2022.

40 As of end 2021, 17 Janssen medicines and 4 Johnson & Johnson Consumer Inc. medicines were included in the WHO’s EML and EMLc.

41 WHO, "Global TB progress at risk," https://www.who.int/news/item/14-10-2020-who-global-tb-progress-at-risk. Accessed February 2022.

42 WHO, "Ending the neglect to attain Sustainable Development Goals: A road map for neglected tropical diseases, 2021–2030," https://apps.who.int/iris/rest/bitstreams/1326801/retrieve.

43 Ibid.

44 The study was completed in collaboration with the KU Leuven Rega Institute and the KU Leuven Centre for Drug Design and Discovery (CD3).

45 WHO, "Antimicrobial resistance," https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

46 WHO, "New report calls for urgent action to avert antimicrobial resistance crisis," https://www.who.int/news/item/29-04-2019-new-report-calls-for-urgent-action-to-avert-antimicrobial-resistance-crisis.

47 AMR Action Fund, "The AMR Action Fund announces its first non-industry investments, raising an additional US$140 million toward addressing antimicrobial resistance (AMR)," https://www.amractionfund.com/resources/the-amr-action-fund-announces-its-first-non-industry-investments-raising-an-additional-us140-million-toward-addressing-antimicrobial-resistance-amr. Accessed February 2022.

48 Expanded global parental leave benefit was applied retroactively beginning July 1, 2021.

49 IPCC Sixth Assessment Report, "FAQ 1: What are the new insights on climate impacts, vulnerability and adaptation from IPCC?" https://www.ipcc.ch/report/ar6/wg2/about/frequently-asked-questions/keyfaq1.

50 Materiality, as used in this Report, and our Priority Topics Assessment process is different than the definition used in the context of filings with the SEC.

Back to Top